Physician profile
Nakul Gupta
NPI 1396905535
$79,618.14
in general payments reported to CMS, 2019-2025
16 companies · $12K in 2025
The $12K reported for 2025 was more than what 97% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $2,709 · 2021: $311 · 2022: $11K · 2023: $3,847 · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,042 · Food and Beverage: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $23,887.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,042.00 |
| Food and Beverage | $2,701.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $53,930.65 | 2019-2025 | Magnetom Terra, Naeotom Alpha, Magnetom Vida |
| Ge Healthcare | $23,185.81 | 2019-2025 | |
| Angiodynamics, INC. | $1,068.44 | 2019 | |
| Eisai INC. | $395.49 | 2019-2025 | |
| Ethicon US, LLC | $349.53 | 2020-2024 | Neuwave |
| Abbvie INC. | $153.29 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $138.43 | 2022-2025 | Zerbaxa, Dificid, Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $118.93 | 2025 | Livtencity |
| Bayer Healthcare Pharmaceuticals INC. | $93.15 | 2019 | |
| Aidoc Medical LTD | $46.88 | 2025 | Briefcase |
| Shionogi INC | $34.22 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.43 | 2025 | Terlivaz |
| Incyte Corporation | $23.11 | 2024 | Pemazyre |
| Mirum Pharmaceuticals, INC. | $22.44 | 2025 | Livmarli |
| Astellas Pharma US INC | $19.21 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nakul Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.